Jason O'Byrne - Nov 15, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Stock symbol
VIR
Transactions as of
Nov 15, 2024
Transactions value $
$0
Form type
4
Date filed
11/18/2024, 01:36 PM
Previous filing
Oct 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +75K $0.00 75K Nov 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +150K $0.00 150K Nov 15, 2024 Common Stock 150K $8.64 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on November 15, 2025, and the remaining shares vest in 36 equal monthly installments thereafter.